Novel HCMV compound of AiCuris in phase IIb trial with bone marrow transplant recipients

11-May-2010 - Germany

AiCuris announced that its novel HCMV inhibitor AIC246 is now being tested in a phase IIb trial with bone marrow transplant recipients. First patients have already been included into the trial. AIC246 is under development for the treatment of HCMV (humane cytomegalovirus) infections in transplant recipients and other immune compromised individuals.

In a first phase II trial in kidney transplant recipients, who developed HCMV viraemia post transplantation, the compound had demonstrated efficacy and good tolerability. “This positive results shall be supported further by our present trial aimed at inhibiting HCMV reactivation in bone marrow transplant patients”, said Prof Helga Rübsamen-Schaeff, CEO of AiCuris. Another aim of the trial is to determine the right dose for the following phase III studies.

„Based on the existing data we expect that AIC246 has the potential to significantly improve the prophylaxis and treatment strategies of HCMV infections in immune compromised patients”, said Dr. Holger Zimmermann, CSO of AiCuris. Apart from the good tolerability demonstrated in the first phase II trial, the compound had shown efficacy in the treatment of one patient who developed viraemia due to multi-resistant (Ganciclovir, Foscarnet and Cidofovir) HCMV. Dr. Holger Zimmermann: “The medical need for new and well-tolerated therapeutic options against HCMV is still high – especially for immune compromised individuals and for newborn children.”

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...

Last viewed contents

DURAN Group launches anniversary campaign to celebrate 120 years of laboratory glassware

DURAN Group launches anniversary campaign to celebrate 120 years of laboratory glassware

MedMira Extends Market Reach into Southeast Asia with Contract for One Million HIV Tests - SE Asia Latest Target Market in Growing Global Distributor Network

SAFC and Novozymes Biopharma extend joint agreement for the exclusive distribution of LONGR3 growth factor

ARIUS Research Signs Anti-Cancer Antibody Discovery Deal with Takeda - Three-Year Collaboration to look for Novel Cancer Treatments

Amorfix announces Michael Sonnenreich as new director and establishment of a scientific advisory board

ALTANA AG: Sale of pharmaceuticals business to Nycomed - Purchase price of approx. EUR4.5 billion

MediGene and The Johns Hopkins University Sign Development Collaboration for First Vaccine Candidates from MediGene's AAVLP Platform - Examination of product candidates for the prevention of HPV-associated diseases

Lexicon Genetics Initiates Clinical Trials of LX1031 for Irritable Bowel Syndrome

AMRI promotes Richard A. Saffee to Vice President and General Manager of Large Scale Manufacturing

Market Opportunities Abound for Life Science Suppliers in Multi-Billion Dollar U.S. Market for Biodefense Research

MIT biologists find that restoring the gene for cancer protein p53 slows spread of advanced tumors

Enzo Biochem Granted European Patent For Displacer Technology To Treat Gene Abnormalities - Methodology Could Make Possible Modification or Corrections of Cell Mutations